NS-229 + Placebo
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Eosinophilic Granulomatosis With Polyangiitis
Conditions
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Trial Timeline
Dec 20, 2023 → Jul 1, 2026
NCT ID
NCT06046222About NS-229 + Placebo
NS-229 + Placebo is a phase 2 stage product being developed by Nippon Shinyaku for Eosinophilic Granulomatosis With Polyangiitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06046222. Target conditions include Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome.
What happened to similar drugs?
6 of 17 similar drugs in Eosinophilic Granulomatosis With Polyangiitis were approved
Approved (6) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06046222 | Phase 2 | Recruiting |
Competing Products
20 competing products in Eosinophilic Granulomatosis With Polyangiitis